Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

Freely Filtered, a NephJC Podcast - A podcast by NephJC Team

FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?